FR1603312A - Injectable vaccine prepns - Google Patents

Injectable vaccine prepns

Info

Publication number
FR1603312A
FR1603312A FR1603312DA FR1603312A FR 1603312 A FR1603312 A FR 1603312A FR 1603312D A FR1603312D A FR 1603312DA FR 1603312 A FR1603312 A FR 1603312A
Authority
FR
France
Prior art keywords
oil
virus
antigen
dispersed
emulsifying agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR1603312A publication Critical patent/FR1603312A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Method for prepn. of vaccines (I). A multiple emulsion is prepared in which an aqueous medium containing the antigen(s), is dispersed in an oil (e.g. Drakeol 6VR, Bayol F, or Arachis) with the aid of an emulsifying agent (5-15% Arlacel A), the particle size being 1-7 mu. This is then dispersed in a second aqueous phase, the ratio (oil:water) being between 3:1 and 1:10, by the use of a suitable emulsifying agent (e.g.Tween 80), and a homogeniser, or ultra-sonic vibration (18000-20000 Hz). The size of the oil particles is 10-50 mu. A more stable emulsion is produced by the addition of 1% agar. Any type of antigen may be used, including influenza virus, Newcastle disease virus, tetanus toxoid, polio virus, Bordetella pertussis bacteria, measles virus, and diptheria toxoid. (1) Low viscosity (2) I is rapidly transported through the body (3) Multiple dose containers can be used.
FR1603312D 1963-10-25 1964-10-23 Injectable vaccine prepns Expired FR1603312A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB42210/63A GB1080994A (en) 1963-10-25 1963-10-25 Injectable emulsions containing antigens

Publications (1)

Publication Number Publication Date
FR1603312A true FR1603312A (en) 1971-04-05

Family

ID=10423339

Family Applications (2)

Application Number Title Priority Date Filing Date
FR992566A Expired FR4083M (en) 1963-10-25 1964-10-23
FR1603312D Expired FR1603312A (en) 1963-10-25 1964-10-23 Injectable vaccine prepns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR992566A Expired FR4083M (en) 1963-10-25 1964-10-23

Country Status (8)

Country Link
BE (1) BE654793A (en)
BR (1) BR6463510D0 (en)
DK (1) DK114855B (en)
ES (1) ES305277A1 (en)
FR (2) FR4083M (en)
GB (1) GB1080994A (en)
NL (1) NL6412206A (en)
SE (1) SE326796B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129923A1 (en) * 1983-06-06 1985-01-02 Duphar International Research B.V Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
FR2649012A1 (en) * 1989-07-03 1991-01-04 Seppic Sa MULTIPHASIC EMULSIONS INJECTABLE
WO1993002665A1 (en) * 1991-07-26 1993-02-18 Smithkline Beecham Corporation W/o microemulsions
EP0597007B1 (en) * 1991-07-26 1996-10-16 Smithkline Beecham Corporation W/o microemulsions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792410B2 (en) * 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Medicinal preparation for intravenous injection
SE8004580L (en) * 1980-06-19 1981-12-20 Draco Ab PHARMACEUTICAL PREPARATION
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
US9724278B2 (en) 2008-06-13 2017-08-08 Colgate-Palmolive Company Oral compositions and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129923A1 (en) * 1983-06-06 1985-01-02 Duphar International Research B.V Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
FR2649012A1 (en) * 1989-07-03 1991-01-04 Seppic Sa MULTIPHASIC EMULSIONS INJECTABLE
WO1991000106A1 (en) * 1989-07-03 1991-01-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Injectable multi-phase emulsions
WO1993002665A1 (en) * 1991-07-26 1993-02-18 Smithkline Beecham Corporation W/o microemulsions
EP0597007B1 (en) * 1991-07-26 1996-10-16 Smithkline Beecham Corporation W/o microemulsions

Also Published As

Publication number Publication date
GB1080994A (en) 1967-08-31
BR6463510D0 (en) 1973-08-02
ES305277A1 (en) 1965-05-01
SE326796B (en) 1970-08-03
NL6412206A (en) 1965-04-26
BE654793A (en) 1965-04-23
FR4083M (en) 1966-04-12
DK114855B (en) 1969-08-11

Similar Documents

Publication Publication Date Title
FR1603312A (en) Injectable vaccine prepns
KR950701822A (en) Combined vaccines comprising hepatitis B surface antigen and other antines
ES2179105T3 (en) PROTEIN ASSISTANTS.
FI925835A (en) VACCINER INNEHAOLLANDE LIPOSOMER
RU2019122996A (en) COMBINED VACCINE FOR PIGS
ES8502870A1 (en) Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained.
ES2097840T3 (en) VACCINE ADJUVANT INCLUDING A TETRAPOLIOL.
SE7512828L (en) CALICIVIRUSVACCIN
ES379642A1 (en) Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization
NL168510B (en) PROCESS FOR THE PREPARATION OF A PREPARATION WITH AN ANTI-ARRHYTHIC EFFECT, INSERTING AN ACTIVE SUBSTANCE IN A FORM SUITABLE FOR SUCH PREPARATIONS, PREPARING PREPARED PREPARATIONS BY USING THE PROCEDURE THROUGH THAT PROCESS AND METHOD OPERATION SUITABLE FOR USE IN THIS METHOD.
JPS6456621A (en) Aluminum hydroxide gel-added hepatitis b vaccine and preparation
ATE258445T1 (en) VACCINE CONTAINING BACTERIN AND TOXOID FROM PASTEURELLA HAEMOLYTICA TYPE A-1
FR2010678A1 (en) Stable polyvalent vaccine for treatment of dogs - active against Carre's disease, hepatitis and leptospirosis
Wu et al. Effect of a stimulating dose of pertussis vaccine on children previously immunized
GB1067463A (en) Preventive treatment for infectious viral equine respiratory disease
Blake EVALUATION OF TYPHOID VACCINES IN THE LABORATORY AND IN A CONTROLLED FIELD TRIAL IN POLAND. PRELIMINARY REPORT
Smith Pneumonic plague in mice: modification of the infection by antibody against specific components of Pasteurella pestis
Prabhu The Vaccine Timeline
FR2265406A1 (en) Hepatitis B vaccine - contains Australian type serum hepatitis antigens in an immunogenic form, alumin and globulins
Diena et al. Transmission of immunity to Neisseria gonorrhoeae from vaccinated hens to embryos
RU97117740A (en) INACTIVATED EMULSIN VACCINE AGAINST CALM SALMONELLES
GB949399A (en) Poliomyelitis vaccines
Katitch Etiology and immunoprophylaxy problems in sheep foot-rot (author's transl)
FR2017251A1 (en) Sustained release foot and mouth disease vaccines in the - form of low viscosity water in oil emulsions
GB770852A (en) Vaccine products and process of producing the same

Legal Events

Date Code Title Description
ST Notification of lapse